Juno Therapeutics (JUNO) Rating Reiterated by Wells Fargo & Co

Wells Fargo & Co reaffirmed their market perform rating on shares of Juno Therapeutics (NASDAQ:JUNO) in a research report report published on Wednesday, The Fly reports. They currently have a $63.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $54.00.

Several other analysts also recently weighed in on JUNO. Morgan Stanley reiterated an equal weight rating and issued a $43.00 price objective (up previously from $27.00) on shares of Juno Therapeutics in a research report on Friday, October 6th. Goldman Sachs Group reiterated a neutral rating and issued a $44.00 price objective on shares of Juno Therapeutics in a research report on Friday, October 6th. Maxim Group reiterated a buy rating and issued a $56.00 price objective (up previously from $34.00) on shares of Juno Therapeutics in a research report on Monday, October 9th. Cowen reiterated a buy rating and issued a $49.00 price objective on shares of Juno Therapeutics in a research report on Friday, October 27th. Finally, Citigroup reiterated a buy rating and issued a $59.00 price objective on shares of Juno Therapeutics in a research report on Tuesday, October 31st. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and seven have given a buy rating to the company. Juno Therapeutics currently has a consensus rating of Hold and a consensus target price of $47.26.

Juno Therapeutics (NASDAQ:JUNO) traded down $3.56 during trading hours on Wednesday, reaching $67.81. The company had a trading volume of 5,220,193 shares, compared to its average volume of 2,846,186. The company has a market cap of $8,148.52, a P/E ratio of -20.06 and a beta of 2.32. Juno Therapeutics has a one year low of $19.07 and a one year high of $74.35. The company has a quick ratio of 4.77, a current ratio of 4.77 and a debt-to-equity ratio of 0.01.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative return on equity of 32.54% and a negative net margin of 332.05%. The firm had revenue of $44.80 million during the quarter, compared to the consensus estimate of $18.12 million. During the same quarter in the previous year, the company posted ($0.57) earnings per share. The business’s revenue was up 115.4% on a year-over-year basis. research analysts anticipate that Juno Therapeutics will post -4.02 EPS for the current fiscal year.

In related news, Director Richard Klausner sold 36,000 shares of the company’s stock in a transaction on Thursday, December 21st. The stock was sold at an average price of $44.76, for a total value of $1,611,360.00. Following the sale, the director now directly owns 744,392 shares of the company’s stock, valued at $33,318,985.92. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Robert Azelby sold 29,131 shares of the company’s stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $68.61, for a total value of $1,998,677.91. Following the completion of the sale, the executive vice president now directly owns 73,330 shares in the company, valued at $5,031,171.30. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 365,337 shares of company stock valued at $17,540,499. 15.08% of the stock is owned by corporate insiders.

A number of hedge funds have recently modified their holdings of the stock. The Manufacturers Life Insurance Company grew its stake in Juno Therapeutics by 7.2% in the second quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock worth $102,000 after purchasing an additional 228 shares during the period. Aperio Group LLC grew its stake in shares of Juno Therapeutics by 4.2% in the third quarter. Aperio Group LLC now owns 29,554 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 1,194 shares during the last quarter. SG Americas Securities LLC grew its stake in shares of Juno Therapeutics by 9.5% in the third quarter. SG Americas Securities LLC now owns 15,254 shares of the biopharmaceutical company’s stock worth $684,000 after acquiring an additional 1,328 shares during the last quarter. Advisor Group Inc. grew its stake in shares of Juno Therapeutics by 141.1% in the third quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock worth $109,000 after acquiring an additional 1,439 shares during the last quarter. Finally, Macquarie Group Ltd. grew its stake in shares of Juno Therapeutics by 17.5% in the third quarter. Macquarie Group Ltd. now owns 9,750 shares of the biopharmaceutical company’s stock worth $437,000 after acquiring an additional 1,450 shares during the last quarter. 69.94% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3147774/juno-therapeutics-juno-rating-reiterated-by-wells-fargo-co.html.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

The Fly

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.